お知らせ • May 07
Regent Pacific Group Limited, Annual General Meeting, May 29, 2026 Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kong お知らせ • Mar 16
Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026 Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026 お知らせ • Aug 15
Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025 Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025 お知らせ • Jun 30
Regent Pacific Group Limited Announces Change in Composition of the Nomination Committee Regent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi. お知らせ • Apr 28
Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025 Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong お知らせ • Mar 17
Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025 Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025 お知らせ • Dec 19
Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in China The Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical. お知らせ • Aug 16
Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024 お知らせ • Apr 28
Regent Pacific Group Limited, Annual General Meeting, May 30, 2024 Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters. お知らせ • Mar 26
Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million. Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies. お知らせ • Mar 16
Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024 お知らせ • Aug 18
Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023 Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023 お知らせ • Jul 23
Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023 Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period"). お知らせ • Feb 18
Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022 Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).